Zilucoplan
A 15-amino-acid macrocyclic peptide that blocks complement C5 and is injected under the skin once a day — the first self-administered complement inhibitor for myasthenia gravis. It was found by mRNA display using amino acids that do not exist in nature, and it reaches patients whose antibodies against the same target do not work.
Zilucoplan is a small ring-shaped peptide you inject under your own skin once a day to treat generalised myasthenia gravis, a disease where the immune system attacks the connection between nerve and muscle. It blocks a protein called C5 that is part of that attack. Because it shuts down part of the immune system, it raises the risk of a rare but dangerous meningitis, so people have to be vaccinated first and the drug is only available through a special safety programme.
What is Zilucoplan?
Zilucoplan is a synthetic macrocyclic peptide that binds complement protein C5 and prevents it being cut into C5a and C5b, which stops the membrane attack complex from forming. It is sold as Zilbrysq for generalised myasthenia gravis in adults who carry antibodies against the acetylcholine receptor, and it was approved in Japan in September 2023, by the FDA on 17 October 2023, and in the European Union on 1 December 2023. What makes it structurally distinctive is how little of it is ordinary protein: fifteen residues closed into a ring by a lactam bridge, containing N-methylated aspartate, tert-leucine, 7-azatryptophan and cyclohexylglycine — none of which the ribosome normally uses — plus a palmitoyl fatty acid and a 24-unit polyethylene glycol chain that bind it to albumin and stretch its half-life to seven or eight days. The result is a 3,562-dalton molecule that does the job of a 148,000-dalton antibody and goes into a prefilled syringe the patient uses at home.
What Zilucoplan Is Investigated For
Zilucoplan has one indication and a trail of honest failures behind it, and the failures are as informative as the approval. In myasthenia gravis the phase 3 RAISE trial randomised 174 anti-AChR-positive patients and met its primary endpoint cleanly — MG-ADL fell 4.39 points against 2.30 on placebo, a 2.09-point difference with p=0.0004 — with 73.1% of treated patients achieving at least a three-point improvement against 46.1% on placebo. The open-label extension has followed 200 patients with benefit sustained to week 60. Outside myasthenia gravis the record is a sequence of well-designed negatives. In immune-mediated necrotising myopathy a phase 2 trial found no effect on creatine kinase despite confirmed target engagement, and the authors drew the right conclusion: complement activation in that disease is probably secondary to muscle injury rather than the cause of it. In amyotrophic lateral sclerosis, regimen A of the HEALEY platform trial enrolled 162 patients and stopped early for futility, with a disease rate ratio of 1.08 and a posterior probability of superiority of 0.24. In paroxysmal nocturnal haemoglobinuria, two phase 2 studies showed useful lactate dehydrogenase reductions in eculizumab-naive patients but rising haemolysis in several who switched from eculizumab, and development in that indication was stopped. The useful reading is that C5 blockade is powerful exactly where complement is doing the damage at the neuromuscular junction, and does nothing where complement is a bystander.
History & Discovery
Zilucoplan was found by a method, not by a hypothesis about a molecule. Ra Pharmaceuticals, founded in Cambridge, Massachusetts in 2008 on macrocyclic peptide chemistry licensed from the Szostak lab at Harvard, ran extreme-diversity mRNA display libraries against complement C5. mRNA display links each peptide to the messenger RNA that encodes it, which permits screening libraries far larger than phage display can manage; the Ra platform's distinctive feature was incorporating amino acids that the ribosome does not normally use, so the libraries explored chemical space outside what genetics can write. The screening hit that emerged was then put through several rounds of peptide medicinal chemistry for potency, stability and pharmacokinetics — a story the team only published in the Journal of Medicinal Chemistry in December 2025, two years after approval. The finished molecule carries the marks of every optimisation step. The lactam bridge between residues 1 and 6 rigidifies the ring. N-methyl aspartate, tert-leucine, 7-azatryptophan and cyclohexylglycine resist proteolysis and tune the binding conformation. The palmitoyl group and the 24-unit PEG chain on the C-terminal lysine bind albumin and stretch the terminal half-life to around 172 hours, which is what makes once-daily subcutaneous dosing possible for a peptide of this size. UCB acquired Ra Pharmaceuticals in April 2020, after the phase 2 myasthenia gravis result had been published in JAMA Neurology but before RAISE read out. The clinical programme then expanded in several directions at once — myasthenia gravis, immune-mediated necrotising myopathy, paroxysmal nocturnal haemoglobinuria, amyotrophic lateral sclerosis, and a 2020 trial in COVID-19 respiratory failure — and contracted again as the non-myasthenia programmes read out negative. Japan approved the drug first, in September 2023, alongside UCB's antibody rozanolixizumab; the FDA followed on 17 October 2023 and the European Commission on 1 December 2023. One footnote from the regulatory record: EU orphan designation, granted in July 2022, was withdrawn from the Union Register in October 2023 at the sponsor's own request.
How It Works
The complement system is a chain of blood proteins that ends by punching holes in whatever it has been pointed at. In myasthenia gravis, antibodies against the acetylcholine receptor recruit that chain to the junction where nerve meets muscle, and the holes damage the junction so the signal to contract gets through poorly. Zilucoplan grabs the protein in the middle of that chain — C5 — and stops it being cut, so the hole-punching machinery never assembles.
Zilucoplan binds complement component 5 and inhibits its cleavage into C5a and C5b, preventing assembly of the terminal complement complex C5b-9, also called the membrane attack complex. In generalised myasthenia gravis the presumed therapeutic mechanism is reduced C5b-9 deposition at the neuromuscular junction, where complement-mediated damage to the postsynaptic membrane is a principal consequence of anti-acetylcholine-receptor antibodies. The binding is more than simple occupancy, and the detail explains several clinical observations. Work published in 2023 showed the peptide binds human C5 with high affinity, competitively inhibits C5 binding to C3b, and blocks cleavage by C5 convertases — then separately interferes with the formation of C5b6, a second point of control downstream of cleavage. This dual mode is why zilucoplan fully prevented in vitro activation of the clinical C5 variants at arginine 885 that respond poorly to eculizumab, and why it also inhibited haemolysis driven by plasmin-mediated non-canonical C5 activation. A 2026 case report put that laboratory finding to work: a patient with anti-AChR-positive myasthenia gravis carrying C5 c.2654G>A (p.Arg885His) had persistent disease and only partial CH50 suppression on ravulizumab, improved the same day on switching to zilucoplan, and had undetectable CH50 thereafter. The same study found the peptide more permeable than a monoclonal C5 antibody in a reconstituted basement-membrane model, which the authors proposed as the basis for its rapid onset. The pharmacology is as unusual as the structure. Complement inhibition measured by sheep red blood cell lysis reached 89.1% within three hours of the first dose in phase 2 and 97.5% by the end of the first week at the approved dose in phase 3, sustained across twelve weeks. Peak plasma concentrations occur three to six hours after a subcutaneous dose, steady state is reached by four weeks, and the terminal half-life is roughly 172 hours — seven to eight days — which is remarkable for a 3,562-dalton peptide and is attributable to the palmitoyl–PEG24 side chain that binds albumin and to greater than 99% plasma protein binding. Two metabolites circulate at about 10% of parent exposure: RA103488, formed mainly by CYP4F2 and pharmacologically similar but far less abundant, and RA102758, formed by protease degradation and inactive. Excretion in urine and faeces is negligible, under 1% of the dose. Zilucoplan is neither a substrate nor an inhibitor of the major CYP enzymes or transporters, and dose adjustment is not required in renal impairment or in mild to moderate hepatic impairment. The dosing is weight-tiered rather than weight-calculated: 16.6 mg below 56 kg, 23 mg from 56 to under 77 kg, and 32.4 mg at 77 kg and above, supplied in three prefilled syringes with colour-coded plunger rods.
Evidence Snapshot
Human Clinical Evidence
Strong for the approved indication and consistently negative elsewhere. RAISE randomised 174 anti-AChR-positive patients across 75 sites in Europe, Japan and North America and met its primary endpoint; a 12-week phase 2 study preceded it; RAISE-XT has followed 200 patients with benefit sustained to week 60. Supporting analyses cover fatigue, corticosteroid and immunosuppressant reduction, and the subgroup never exposed to immunoglobulin or plasma exchange. Against that: a negative randomised phase 2 in immune-mediated necrotising myopathy, a 162-patient ALS regimen stopped for futility, and two phase 2 studies in paroxysmal nocturnal haemoglobinuria after which development in that disease ceased. Real-world cohorts in Italy and France are small and early.
Animal / Preclinical
Modest and mostly supportive rather than foundational, as is typical for a target validated in humans before the molecule existed. The consequential preclinical finding is a safety one: subcutaneous administration throughout gestation in monkeys increased embryofetal death at all doses tested without maternal toxicity, and no no-effect dose was identified. A dedicated reproductive toxicology paper was published in 2025.
Mechanistic Rationale
Strong, specific and unusually well characterised. C5 is a validated target with two approved antibodies ahead of it, and the peptide's particular binding mode has been mapped in detail — competitive inhibition of C5–C3b binding plus interference with C5b6 formation, activity against R885 variants, and inhibition of non-canonical plasmin-mediated activation. The gap between mechanism and benefit is narrow here: complement deposition at the neuromuscular junction is directly observable, and the drug's failures in other diseases are explained by the same framework.
Research Gaps & Open Questions
What the current literature has not yet settled about Zilucoplan:
- 01How often morphea actually occurs, and why. Ten cases in 213 open-label patients is a rate from uncontrolled follow-up, and the question of whether daily subcutaneous injection into a limited area contributes, or whether complement inhibition itself promotes fibrosis, has no answer.
- 02Whether zilucoplan has a genuine advantage in patients carrying C5 polymorphisms. The in vitro evidence against the R885 variants is strong and one case report is persuasive, but no systematic genotyping study has been done in myasthenia gravis and the prevalence of these variants outside East Asian populations is poorly characterised.
- 03Whether daily subcutaneous dosing carries a different meningococcal risk profile than intermittent intravenous antibody. Both maintain inhibition, but the exposure curves differ and the registries are not large enough to compare.
- 04Whether it works in myasthenic crisis. Several case reports and small series describe rapid improvement, including weaning from mechanical ventilation, but there is no trial and crisis patients were excluded from the registration programme.
- 05Where it sits against the FcRn blockers. Network meta-analyses and matching-adjusted indirect comparisons exist, but every one of them is constructed from trials with different populations, endpoints and placebo responses, and none substitutes for a head-to-head.
- 06Pregnancy. The monkey data showing embryofetal death at all doses with no no-effect level, set against an ex vivo placental transfer rate of only 0.5%, is an unresolved contradiction that only registry data will settle.
- 07Why the eculizumab-to-zilucoplan switch produced no measurable improvement while the ravulizumab switch did. The 26-patient open-label study found exactly that split, and the explanation — different trough coverage, patient selection, or chance in a small sample — is unknown.
- 08Whether the negative results in necrotising myopathy, ALS and PNH say something general about where complement inhibition can and cannot help, or whether the doses, durations and endpoints were simply wrong in each case.
Forms & Administration
Subcutaneous injection once daily from a single-dose prefilled syringe, intended for use under healthcare supervision but self-administered by patients after training. Three strengths exist and the right one is chosen by actual body weight: 16.6 mg/0.416 mL under 56 kg, 23 mg/0.574 mL from 56 to under 77 kg, and 32.4 mg/0.81 mL at 77 kg and above, distinguished by rubine red, orange and dark blue plunger rods. Syringes are stored refrigerated in the original carton and brought to room temperature for 30 to 45 minutes before injecting, or kept at room temperature for up to three months — but once out of the fridge they do not go back. Injection sites are the abdomen, thighs or backs of the upper arms, rotated each day and avoiding scars and stretch marks; injections into the upper outer arm need a caregiver. There is no preservative and no intravenous form. A missed dose is taken as soon as possible and then the normal schedule resumes, with never more than one dose in a day.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Weight-tiered fixed doses: 16.6 mg for body weight under 56 kg, 23 mg for 56 to under 77 kg, and 32.4 mg for 77 kg and above. These correspond to the 0.3 mg/kg dose used throughout the clinical programme.
Frequency
Once daily by subcutaneous injection, at approximately the same time each day.
Timing Considerations
Time of day
The same time each day, patient's choice
Relative to meals
No relationship to food
Relative to exercise
Not tied to exercise timing.
Steady state is reached by about four weeks and the terminal half-life is seven to eight days, so a single missed dose does not collapse complement inhibition — but the daily schedule is what the trials tested and what the label specifies.
Cycle Length
Continuous and indefinite. Generalised myasthenia gravis is a chronic autoimmune disease and complement inhibition only works while it is maintained; there is no cycling, loading or tapering schedule, and stopping returns complement activity to baseline.
Protocol Notes
Two things must happen before the first dose. Meningococcal vaccination for serogroups A, C, W, Y and B has to be complete or updated at least two weeks beforehand, following ACIP's schedule for patients receiving complement inhibitors rather than the schedule printed in the vaccines' own labelling — and if treatment cannot wait, antibacterial prophylaxis is given and vaccines follow as soon as possible. Baseline amylase and lipase also have to be drawn, because pancreatitis and pancreatic cysts have been reported and later enzyme rises need a reference point. The dose is chosen from actual body weight, not calculated, and the three prefilled syringes carry colour-coded plunger rods to make the choice visible: rubine red for 16.6 mg, orange for 23 mg, dark blue for 32.4 mg. Patients self-inject after training. Syringes come out of the fridge 30 to 45 minutes before use to reach room temperature — never heated or microwaved — and a syringe kept at room temperature does not go back into the fridge. The product is preservative-free, each syringe is single-dose, and any remainder is discarded. Injection sites are the abdomen, thighs or the backs of the upper arms, rotated daily, avoiding tender, bruised, reddened or hardened skin and avoiding scars and stretch marks; the upper outer arm requires a caregiver. Site rotation deserves more attention than usual here, given that injection-site reactions occurred in 29% of trial patients and that morphea has since appeared in the postmarketing section of the label. A missed dose is given as soon as possible, after which the regular schedule resumes, and never more than one dose in a day.
Zilucoplan is a prescription-only drug dispensed in the United States exclusively through a restricted REMS programme because of the risk of serious meningococcal infection. It is approved only for adults with anti-AChR-antibody-positive generalised myasthenia gravis. The figures above describe approved practice and are not guidance for anyone to act on independently.
Timeline of Effects
Onset
Faster than most immunological treatments, because the target is a circulating protein rather than a cell population. Complement inhibition measured by sheep red blood cell lysis reached 89.1% within three hours of the first dose in the phase 2 study, and 97.5% by the end of the first week at the approved dose in RAISE. Symptom change follows within days to weeks: in the open-label extension, patients crossing over from placebo showed improvement in MG-ADL at the first weekly assessment, and case reports in myasthenic crisis describe improvement within a day or two.
Peak Effect
The twelve-week trial captured most but not all of the effect. In RAISE-XT, patients who had received active drug in the parent study continued improving through week 24 and then held steady to week 60, and those switching from placebo reached a comparable level twelve weeks after switching. Pharmacokinetic steady state arrives around four weeks. In practical terms, judging response at three months is reasonable, and expecting further gradual gain through six months is consistent with the data.
After Discontinuation
Complement activity returns as the drug clears, over roughly a week to a fortnight given the 172-hour terminal half-life, and myasthenic symptoms return with it. There is no disease modification here — the drug blocks an effector pathway and does nothing to the autoantibodies or the B cells producing them. The clinically important corollary runs the other way: meningococcal susceptibility also resolves as complement recovers, but the vaccination requirement and revaccination schedule should be managed on the assumption of continued risk while any inhibition persists.
Monitoring & Measurement
Bloodwork & Labs
- •Serum amylase and lipase — required at baseline before the first dose and tracked afterwards, because pancreatitis and pancreatic cysts have been reported and enzyme elevations occurred in 5–7% of trial patients
- •CH50 or another total haemolytic complement assay — not a labelled requirement, but the practical way to confirm complement blockade, and the test that identified incomplete suppression in the reported C5 variant case
- •Meningococcal vaccination status and dates, maintained as an active record rather than a one-off check, since revaccination depends on treatment duration
- •Full blood count, where transient eosinophil elevations of uncertain significance were seen in trials
- •Anti-acetylcholine-receptor antibody titre at diagnosis — required to confirm eligibility, though it is not used to follow response
Functional & Performance Tests
- •MG-ADL (Myasthenia Gravis Activities of Daily Living), an eight-item patient-reported scale from 0 to 24 — the primary endpoint in RAISE, where a three-point improvement defines response
- •QMG (Quantitative Myasthenia Gravis), a 13-item examiner-administered scale from 0 to 39, with a five-point improvement as the usual response threshold
- •MGC (Myasthenia Gravis Composite) and MG-QOL-15, used in real-world cohorts alongside the two trial scales
- •Skin examination at each visit, particularly after the first year — the morphea cases in the extension studies mostly began beyond twelve months, and injection sites are the obvious place to look
- •Forced vital capacity or single-breath count in anyone with bulbar or respiratory involvement, as part of standard myasthenia care rather than drug monitoring
When to Test
Amylase and lipase before the first dose. Meningococcal vaccination complete at least two weeks before starting. MG-ADL and QMG at baseline and then at intervals through the first twelve weeks, which is the window in which the trials established benefit; real-world cohorts have used week 1, 4, 12, 24 and 48. Skin examination should continue well beyond the first year.
Interpretation & Notes
Two things are easy to get wrong when reading these numbers. The first is the placebo response, which in myasthenia gravis is large: 46.1% of placebo patients in RAISE achieved a three-point MG-ADL improvement and 33% achieved a five-point QMG improvement. Any individual improvement after starting a new drug has to be read against that background, which is why the trial's effect size — about two points on each scale — is the honest measure of what the drug adds rather than the raw change from baseline. The second is that complement inhibition and clinical benefit are not the same measurement. Zilucoplan reliably produces greater than 95% complement inhibition within a week in essentially everyone, so a CH50 that is suppressed tells you the drug is in the system, not that the patient is responding. The necrotising myopathy trial is the clearest illustration: full target engagement, no clinical effect. Conversely, a CH50 that is not fully suppressed on an adequate dose is genuinely informative, and in at least one reported case led to the discovery of a C5 variant and a change of drug.
Common Questions
How does it compare with eculizumab and ravulizumab?
They hit the same protein but they are not interchangeable, and three differences matter. Route and schedule: zilucoplan is a daily subcutaneous injection the patient gives themselves, while the two antibodies are intravenous infusions given in a clinic every two or eight weeks. Binding site: zilucoplan binds a different epitope on C5 and uses a dual mechanism — it competitively blocks C5 binding to C3b and also interferes with C5b6 formation — which means it still works against the C5 R885 variants that respond poorly to eculizumab. Tissue penetration: in a reconstituted basement-membrane model the peptide was more permeable than a monoclonal C5 antibody, which the authors offered as a rationale for its rapid onset. No randomised head-to-head has ever been run. A 26-patient open-label switching study found that patients coming off ravulizumab improved meaningfully while those coming off eculizumab did not, and 76.9% preferred the injection to the infusion — a real-world signal, but single-arm, unblinded and small.
Why does it need a REMS and meningococcal vaccination?
Because blocking C5 removes the terminal complement pathway, which is the body's main defence against Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred with complement inhibitors in both vaccinated and unvaccinated patients, and the boxed warning reflects that. Vaccination for serogroups A, C, W, Y and B must be completed or updated at least two weeks before the first dose, following the ACIP schedule for patients on complement inhibitors — which differs from the schedule in the vaccines' own labelling. If treatment cannot wait, antibacterial prophylaxis is given and vaccines follow as soon as possible. In the US the drug is only dispensed through the ZILBRYSQ REMS, which requires prescriber enrolment, pharmacy certification and documented patient counselling. Vaccination reduces the risk but does not eliminate it, which is why the label insists on monitoring regardless.
What is morphea and why does it appear on this label?
Morphea is localised scleroderma — patches of skin that thicken and harden as collagen accumulates. It is now in the postmarketing section of the US label, where the open-label extension studies of 213 patients recorded morphea in 10 of them (5%), mostly starting more than a year into treatment and mostly mild to moderate, with one patient stopping the drug because of it. Three separate case reports appeared in the dermatology literature in September and October 2026, in JAMA Dermatology and JAAD Case Reports, including one case managed with methotrexate and UVA1 phototherapy. A 5% rate found in open-label follow-up is not a rate established by a controlled trial, and a drug that is injected daily into the same few areas of skin invites questions about whether site reactions and fibrosis share a mechanism — but the signal is on the label and the onset pattern of more than a year means it would have been easy to miss in a twelve-week trial.
Why does the label require amylase and lipase before starting?
Pancreatitis and pancreatic cysts have been reported in patients on zilucoplan, and the label asks for baseline lipase and amylase so that later elevations can be interpreted. In the placebo-controlled trial, raised lipase occurred in 7% of treated patients versus 0% on placebo and raised amylase in 5% versus 1%. The instruction is to stop the drug in anyone with suspected pancreatitis and manage them until it is ruled out or resolved. This was a late addition in regulatory terms: the dosage and administration, contraindications and warnings sections were all revised in February 2025.
Does it work for other complement diseases?
On the evidence so far, no — and the trials that found that out were good ones. Immune-mediated necrotising myopathy looked like an obvious target, because the autoantibodies activate complement and complement deposits on non-necrotic muscle fibres. A randomised phase 2 trial found no difference in creatine kinase at eight weeks despite confirmed target engagement, and the investigators concluded that complement activation there is probably a consequence of muscle injury rather than its cause. In amyotrophic lateral sclerosis, 162 patients were randomised within the HEALEY platform and the regimen was stopped early for futility. In paroxysmal nocturnal haemoglobinuria, patients switched from eculizumab saw lactate dehydrogenase rise rather than fall, which the authors attributed to high C3b density on red cells permitting C5 activation that the peptide could not block; development in PNH was discontinued.
Who Zilucoplan Is NOT For
- •Initiation in a patient with an unresolved serious Neisseria meningitidis infection — the only contraindication on the current US label.
- •Patients not up to date with meningococcal vaccination per ACIP recommendations should not begin treatment unless the urgency justifies starting with antibacterial prophylaxis and immediate vaccination.
- •Suspected pancreatitis — treatment is stopped and withheld until pancreatitis is ruled out or resolved.
- •Pregnancy warrants serious caution rather than a formal contraindication: zilucoplan given to pregnant monkeys throughout gestation increased embryofetal death at all doses tested, with no no-effect dose identified, and there are no human data.
- •Children and adolescents — safety and effectiveness have not been established under 18.
- •Caution rather than prohibition in any other active systemic infection, because terminal complement blockade is not selective for meningococcus.
- •Severe hepatic impairment, where the pharmacokinetics have not been studied at all.
Drug & Supplement Interactions
No dedicated clinical drug-interaction studies have been performed, and the in vitro work suggests few are needed. Zilucoplan is not a substrate of the major cytochrome P450 enzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A) or of P-glycoprotein, BCRP, OATP1B1 or OATP1B3, and clinically relevant interactions with substrates of those enzymes, of the UGT family, or of the usual uptake and efflux transporters are considered unlikely. One pharmacokinetic detail is worth knowing: the active metabolite RA103488 is formed mainly by CYP4F2, though since it circulates at about 10% of parent exposure and contributes little activity, perturbing that pathway is unlikely to matter. The meaningful interactions are immunological rather than metabolic. Vaccines are the clearest case, and the direction is counterintuitive: meningococcal vaccination is not merely compatible with zilucoplan but mandatory before it, on a schedule specific to complement-inhibitor recipients that differs from the vaccines' own labelling, with revaccination considered according to how long treatment continues. Antibacterial prophylaxis becomes part of the regimen when urgency forces treatment before vaccination has taken effect. Live vaccines in a patient with blocked terminal complement warrant specialist advice. Combining zilucoplan with another complement C5 inhibitor has no established role and is not supported by any trial; the switching study that exists moved patients from eculizumab or ravulizumab onto zilucoplan rather than adding it. Combination with an FcRn blocker has been described in case reports for refractory disease, which illustrates that the question is live but not that it is answered. The background myasthenia regimen — acetylcholinesterase inhibitors, corticosteroids and non-steroidal immunosuppressants — was continued at stable doses throughout the trials, and a separate analysis has tracked how much of that burden comes down over long-term treatment.
Safety Profile
Common Side Effects
Cautions
- • Serious meningococcal infection is the boxed warning and the central risk. Infections have been life-threatening and fatal in both vaccinated and unvaccinated patients on complement inhibitors, and can progress within hours. Vaccination against serogroups A, C, W, Y and B must be completed at least two weeks before the first dose, per ACIP's schedule for complement-inhibitor recipients.
- • In the United States the drug is available only through the ZILBRYSQ REMS, requiring prescriber enrolment, pharmacy certification, documented counselling and an antibacterial prophylaxis prescription where urgent treatment precedes vaccination.
- • Pancreatitis and pancreatic cysts have been reported. Baseline amylase and lipase are required before starting, and the drug is stopped in anyone with suspected pancreatitis.
- • Caution is advised with any other systemic infection, since the terminal complement pathway is blocked across the board and not only against meningococcus.
- • Animal reproductive data are concerning: subcutaneous zilucoplan given to pregnant monkeys throughout gestation increased embryofetal death at every dose tested, in the absence of maternal toxicity, and no no-effect dose was identified. A pregnancy exposure registry exists.
- • Myasthenia gravis worsening was reported in 26% of patients in the open-label extension, which is a feature of the disease as much as the drug but matters for anyone interpreting long-term tolerability data.
- • Safety and effectiveness in children have not been established, and the trials enrolled too few patients over 65 to characterise that group separately.
What We Don't Know
The long-term dermatological picture is the biggest open question. Morphea at 5% in open-label follow-up, with onset typically beyond a year, is a signal that twelve-week registration trials could not have found and that no controlled dataset has quantified. Beyond that: whether daily subcutaneous dosing carries a different infection risk profile from intermittent intravenous antibody, since complement inhibition is continuous either way but trough exposure differs; whether zilucoplan has a durable advantage in patients with C5 polymorphisms, which rests so far on in vitro data and a single case report; whether the drug is useful in myasthenic crisis, where several case series have reported rapid improvement but no trial exists; and what happens in pregnancy, where an ex vivo placental transfer rate of 0.5% sits alongside monkey data showing embryofetal death at all doses.
Legal Status
United States
FDA-approved and marketed, with restrictions. Zilbrysq was approved on 17 October 2023 under NDA 216834 for generalised myasthenia gravis in adults who are anti-acetylcholine-receptor antibody positive. It carries a boxed warning for serious meningococcal infections and is dispensed only through the ZILBRYSQ REMS, which requires prescriber enrolment, pharmacy certification, documented counselling and vaccination verification. It is not a controlled substance. The label was substantially revised in February 2025 — boxed warning, dosage and administration, contraindications and three warnings sections — and the currently published version carries a February 2026 revision. Drugs@FDA additionally records an efficacy supplement approved on 15 October 2026 for which revised labelling had not yet published as of late October 2026, so anyone relying on the exact indication wording should check the current prescribing information.
International
Authorised in the European Union since 1 December 2023, held by UCB Pharma S.A., as an add-on to standard therapy for anti-AChR-antibody-positive generalised myasthenia gravis in adults. EU orphan designation, granted on 18 July 2022, was withdrawn from the Union Register in October 2023 at the holder's request. Japan approved zilucoplan in September 2023 — the first approval anywhere — for adults with generalised myasthenia gravis inadequately controlled on steroids or other immunosuppressants, alongside UCB's rozanolixizumab on the same day.
Sports & Competition
Not prohibited, and no class plausibly reaches it. Zilucoplan appears nowhere on the WADA 2027 Prohibited List, and complement inhibitors are not covered by any substance class — S2 governs peptide hormones, growth factors and mimetics with performance-relevant endocrine or haematological action, which a C5 blocker is not. There is no performance rationale either: the drug relieves weakness caused by autoimmune destruction of the neuromuscular junction and does nothing for an intact one. An athlete with generalised myasthenia gravis would be taking it as ordinary treatment for a serious disease, though as with any prescription in elite sport it is worth confirming current status with an anti-doping organisation rather than relying on absence from a list.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Zilucoplan is a biosimilar or a peptide copy of eculizumab.
Reality
It has no structural relationship to eculizumab whatsoever. Eculizumab is a humanised monoclonal antibody of about 148,000 daltons; zilucoplan is a 15-residue synthetic macrocyclic peptide of 3,562 daltons, discovered by mRNA display and made by chemical synthesis. They converge on the same protein from different directions and bind different epitopes, which is exactly why zilucoplan works against C5 variants that defeat eculizumab.
Myth
Being vaccinated against meningococcus makes the drug safe.
Reality
It reduces the risk substantially and does not eliminate it. The label states plainly that patients on zilucoplan remain at increased risk for invasive meningococcal disease even after developing antibodies following vaccination, and that life-threatening and fatal infections have occurred in vaccinated patients on complement inhibitors. That is the reason the monitoring instruction stands independently of vaccination status, and the reason the REMS requires counselling rather than just a vaccination record.
Myth
A failed trial in another disease means the drug does not really work.
Reality
The opposite reading is better supported. Zilucoplan achieved 97.5% complement inhibition in the necrotising myopathy trial and still did nothing for creatine kinase — target engagement was confirmed, the target just was not driving the disease. In ALS the regimen was stopped for futility on a disease rate ratio of 1.08. These are tests of the complement hypothesis in those conditions, not tests of the molecule, and they strengthen rather than weaken the case that the myasthenia gravis benefit reflects real complement-mediated damage at the neuromuscular junction.
Myth
Self-injection means it is a simpler, lower-commitment treatment.
Reality
It moves the burden rather than removing it. There is no infusion chair, but there is an injection every single day without a break, a restricted dispensing programme, a vaccination schedule that must be completed two weeks before starting and maintained afterwards, baseline and ongoing pancreatic enzyme monitoring, and a boxed warning requiring the patient to know the signs of meningococcal infection and seek care immediately. Patients in the switching study did prefer it to infusion, by 76.9% — but preference is not the same as simplicity.
Myth
Peptides cannot last long enough in the body to be dosed once a day.
Reality
Not without help, which is precisely what the design supplies. Zilucoplan's C-terminal lysine carries a palmitoyl fatty acid and a 24-unit polyethylene glycol chain that bind serum albumin, and the molecule is over 99% plasma protein bound. The terminal half-life is around 172 hours — seven to eight days — for a molecule one fortieth the mass of an antibody. The unnatural amino acids and the lactam macrocycle handle the other half of the problem, which is proteolysis.
Published Research
31 studiesComparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons
Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development
Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper
Fibrosing Skin Disorder Associated With Zilucoplan
Auroy A et al., JAMA Dermatology 2026. One of three dermatology reports published within weeks of each other in autumn 2026 describing progressive skin induration and fibrosis during zilucoplan treatment. The US label's postmarketing section now records morphea in 10 of 213 patients (5%) in open-label extension studies, most beginning more than a year after starting — an onset pattern that a twelve-week registration trial could not have detected.
Zilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy
A rare case of morphea following zilucoplan treatment for generalized myasthenia gravis
Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland
Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis
Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France
Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report
Itagaki Y et al., Neuromuscular Disorders 2026. The first report of ravulizumab non-response and robust zilucoplan response in myasthenia gravis with this C5 variant — persistent disease and only partial CH50 suppression on ravulizumab, same-day improvement and undetectable CH50 after switching. Turns an in vitro finding into a clinical argument for C5 genotyping and CH50 testing in apparent non-responders. A single patient, so the strength lies in the mechanistic coherence rather than the sample size.
Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG)
Ye P et al., Journal of Medicinal Chemistry 2025. The discovery account from the Ra Pharmaceuticals team, published two years after approval. The hit came from extreme-diversity mRNA display against C5 using unnatural amino acids, and the paper traces the medicinal chemistry that turned a screening hit into a molecule with the potency, stability and pharmacokinetics to support once-daily subcutaneous dosing.
Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study
Freimer M et al., Ther Adv Neurol Disord 2025. 26 stable patients switched from eculizumab (16) or ravulizumab (10) for 12 weeks. The headline improvement was driven almost entirely by the ravulizumab group (MG-ADL −2.41, p=0.03) while the eculizumab group did not separate; 76.9% preferred subcutaneous injection to infusion. Single-arm, unblinded and small, so the preference data are more robust than the efficacy data.
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis
Efficacy of zilucoplan in patients with generalised myasthenia gravis who have not previously received immunoglobulin or plasma exchange: A subgroup analysis
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis
Subcutaneous zilucoplan: Evaluation of reproductive toxicology
Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
Paganoni S et al., JAMA Network Open 2025. Regimen A of the HEALEY ALS Platform Trial: 162 participants randomised 3:1 against a shared placebo group of 164. The disease rate ratio common to ALSFRS-R and survival was 1.08 (95% credible interval 0.87–1.31) with a posterior probability of superiority of 0.24, and the regimen stopped early for futility. A clean negative, and an illustration of the platform design working as intended.
Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study
Howard JF Jr et al., Ther Adv Neurol Disord 2024. 200 patients, median exposure 1.2 years. MG-ADL improvements continued to week 24 and held to week 60, and patients switching from placebo improved within the first week. The tolerability numbers deserve equal billing: 94% had a treatment-emergent adverse event, with myasthenia gravis worsening in 26% and COVID-19 in 25%.
Improvement of fatigue in generalised myasthenia gravis with zilucoplan
Zilucoplan: First Approval
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
Tang GQ et al., Frontiers in Immunology 2023. Showed zilucoplan competitively inhibits C5 binding to C3b and separately interferes with C5b6 formation — the dual mechanism that explains why it fully blocks the clinical C5 R885 variants that respond poorly to eculizumab, and why it inhibits plasmin-mediated non-canonical C5 activation. Also found greater permeability than a monoclonal C5 antibody in a reconstituted basement-membrane model.
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria
Kulasekararaj AG et al., Haematologica 2024. Two 12-week single-arm studies in 29 patients. Eculizumab-naive patients had rapid and sustained lactate dehydrogenase reductions, but among the 19 switched from eculizumab median LDH rose by 230 U/L and transfusion-dependent patients were not adequately controlled despite complete complement inhibition — attributed to high C3b density on red cells permitting C5 activation the peptide could not block. Development in PNH was discontinued.
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
Howard JF Jr et al., Lancet Neurology 2023. The registration trial: 174 anti-AChR-positive patients at 75 sites randomised to 0.3 mg/kg daily subcutaneous zilucoplan or placebo for 12 weeks. MG-ADL fell by a least-squares mean of 4.39 points versus 2.30 (difference −2.09, p=0.0004) and QMG by 6.19 versus 3.25. The most common treatment-emergent event was injection-site bruising. One death occurred in each arm, neither considered drug-related. Funded by UCB Pharma, with several authors employed by the sponsor.
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial
Mammen AL et al., Lancet Rheumatology 2023. 27 patients with anti-HMGCR or anti-SRP antibodies, eight weeks of treatment, no difference in creatine kinase despite confirmed target engagement (−9.86% versus −20.72%, p=0.46). The interpretation is the valuable part: complement activation in this myopathy is probably secondary to muscle injury rather than the driver of it.
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized Clinical Trial
ZILBRYSQ (zilucoplan) injection — US Prescribing Information
Zilbrysq — European Public Assessment Report (EMA)
Quick Facts
- Class
- Complement C5 Inhibitor (Macrocyclic Peptide)
- Tier
- B
- Evidence
- Strong
- Safety
- Moderate Data
- Updated
- Oct 2026
- Citations
- 31PubMed
Also known as
Tags
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.